Can a common antibiotic keep up with severe burns?
NCT ID NCT01497990
First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time
Summary
Researchers are studying how the antibiotic ertapenem behaves in patients with severe burns who are on breathing machines. The trial measures drug levels in the blood after two intravenous doses to see how the body processes the medicine. They also check whether a standard 1-gram dose keeps drug concentrations high enough to fight the bacteria that commonly cause early infections in burn patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ertapenem, an antibiotic given by intravenous injection
- What this could lead to
- If the standard dose keeps drug levels high enough in burn patients, doctors could use it with more confidence to treat early infections in people with severe burns.
- What could go wrong
- The study is very small, with only eight participants, so its results may not apply to all burn patients. Burn injuries change how the body processes drugs, and the findings might show that the standard dose is not enough or that dosing needs to be adjusted.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
8 people
The number who actually took part.
- Start date
-
Jan 2010
- Finished
-
Sep 2011
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients aged 18 to 70 years * Burned on 30 to 60% of their body surface * Mechanical ventilation * Hospitalized in the intensive care unit of Nantes University Hospital for less than 8 days. * Which the family gave consent * insured Exclusion Criteria: * Patients whose family refused to sign the consent for participation. * Patients allergic to beta lactam * Patients with renal failure with creatinine clearance \<80 ml.mn-1 * Pregnant women * Persons protected by the law
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Burn patients are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nantes University Hospital
Nantes, 44000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.